nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezogabine—NAT2—urinary bladder cancer	0.66	1	CbGaD
Ezogabine—UGT1A1—Etoposide—urinary bladder cancer	0.0338	0.584	CbGbCtD
Ezogabine—CYP2A6—Fluorouracil—urinary bladder cancer	0.024	0.416	CbGbCtD
Ezogabine—NAT2—urine—urinary bladder cancer	0.0159	0.272	CbGeAlD
Ezogabine—UGT1A1—urine—urinary bladder cancer	0.0059	0.101	CbGeAlD
Ezogabine—KCNQ4—prostate gland—urinary bladder cancer	0.005	0.0853	CbGeAlD
Ezogabine—KCNQ5—prostate gland—urinary bladder cancer	0.00487	0.0829	CbGeAlD
Ezogabine—NAT2—renal system—urinary bladder cancer	0.0039	0.0665	CbGeAlD
Ezogabine—KCNQ5—female reproductive system—urinary bladder cancer	0.00266	0.0453	CbGeAlD
Ezogabine—UGT1A4—renal system—urinary bladder cancer	0.00251	0.0428	CbGeAlD
Ezogabine—KCNQ5—vagina—urinary bladder cancer	0.0024	0.0409	CbGeAlD
Ezogabine—KCNQ3—female reproductive system—urinary bladder cancer	0.00213	0.0363	CbGeAlD
Ezogabine—UGT1A1—prostate gland—urinary bladder cancer	0.00212	0.0361	CbGeAlD
Ezogabine—UGT1A9—renal system—urinary bladder cancer	0.00211	0.0359	CbGeAlD
Ezogabine—KCNQ2—female reproductive system—urinary bladder cancer	0.00196	0.0334	CbGeAlD
Ezogabine—CYP2A6—prostate gland—urinary bladder cancer	0.00179	0.0304	CbGeAlD
Ezogabine—KCNQ5—lymph node—urinary bladder cancer	0.00155	0.0265	CbGeAlD
Ezogabine—CYP2A6—seminal vesicle—urinary bladder cancer	0.00151	0.0257	CbGeAlD
Ezogabine—UGT1A1—renal system—urinary bladder cancer	0.00144	0.0246	CbGeAlD
Ezogabine—CYP2A6—vagina—urinary bladder cancer	0.000881	0.015	CbGeAlD
Ezogabine—Hepatobiliary disease—Etoposide—urinary bladder cancer	0.000269	0.00302	CcSEcCtD
Ezogabine—Visual impairment—Cisplatin—urinary bladder cancer	0.000268	0.00301	CcSEcCtD
Ezogabine—Coordination abnormal—Doxorubicin—urinary bladder cancer	0.000268	0.00301	CcSEcCtD
Ezogabine—Alopecia—Gemcitabine—urinary bladder cancer	0.000264	0.00296	CcSEcCtD
Ezogabine—Anxiety—Thiotepa—urinary bladder cancer	0.000262	0.00295	CcSEcCtD
Ezogabine—Eye disorder—Cisplatin—urinary bladder cancer	0.00026	0.00292	CcSEcCtD
Ezogabine—Coma—Epirubicin—urinary bladder cancer	0.00026	0.00292	CcSEcCtD
Ezogabine—Alopecia—Fluorouracil—urinary bladder cancer	0.00026	0.00291	CcSEcCtD
Ezogabine—Confusional state—Thiotepa—urinary bladder cancer	0.000254	0.00286	CcSEcCtD
Ezogabine—Urinary tract disorder—Etoposide—urinary bladder cancer	0.000252	0.00283	CcSEcCtD
Ezogabine—Infection—Thiotepa—urinary bladder cancer	0.000251	0.00281	CcSEcCtD
Ezogabine—Urethral disorder—Etoposide—urinary bladder cancer	0.00025	0.00281	CcSEcCtD
Ezogabine—Nervous system disorder—Thiotepa—urinary bladder cancer	0.000247	0.00278	CcSEcCtD
Ezogabine—Thrombocytopenia—Thiotepa—urinary bladder cancer	0.000247	0.00277	CcSEcCtD
Ezogabine—Alopecia—Cisplatin—urinary bladder cancer	0.000246	0.00276	CcSEcCtD
Ezogabine—Malnutrition—Cisplatin—urinary bladder cancer	0.000242	0.00272	CcSEcCtD
Ezogabine—Ill-defined disorder—Gemcitabine—urinary bladder cancer	0.000241	0.00271	CcSEcCtD
Ezogabine—Vision blurred—Fluorouracil—urinary bladder cancer	0.000241	0.00271	CcSEcCtD
Ezogabine—Coma—Doxorubicin—urinary bladder cancer	0.000241	0.0027	CcSEcCtD
Ezogabine—Eye disorder—Etoposide—urinary bladder cancer	0.000238	0.00268	CcSEcCtD
Ezogabine—Malaise—Gemcitabine—urinary bladder cancer	0.000235	0.00263	CcSEcCtD
Ezogabine—Muscle spasms—Cisplatin—urinary bladder cancer	0.000233	0.00262	CcSEcCtD
Ezogabine—Leukopenia—Gemcitabine—urinary bladder cancer	0.000233	0.00261	CcSEcCtD
Ezogabine—Leukopenia—Fluorouracil—urinary bladder cancer	0.000229	0.00257	CcSEcCtD
Ezogabine—Vision blurred—Cisplatin—urinary bladder cancer	0.000228	0.00257	CcSEcCtD
Ezogabine—Tremor—Cisplatin—urinary bladder cancer	0.000227	0.00255	CcSEcCtD
Ezogabine—Paraesthesia—Thiotepa—urinary bladder cancer	0.000227	0.00254	CcSEcCtD
Ezogabine—Alopecia—Etoposide—urinary bladder cancer	0.000225	0.00253	CcSEcCtD
Ezogabine—Ill-defined disorder—Cisplatin—urinary bladder cancer	0.000225	0.00253	CcSEcCtD
Ezogabine—Somnolence—Thiotepa—urinary bladder cancer	0.000224	0.00252	CcSEcCtD
Ezogabine—Dyspepsia—Thiotepa—urinary bladder cancer	0.000222	0.00249	CcSEcCtD
Ezogabine—Osteoarthritis—Methotrexate—urinary bladder cancer	0.000221	0.00248	CcSEcCtD
Ezogabine—Increased appetite—Epirubicin—urinary bladder cancer	0.00022	0.00247	CcSEcCtD
Ezogabine—Discomfort—Gemcitabine—urinary bladder cancer	0.000219	0.00246	CcSEcCtD
Ezogabine—Malaise—Cisplatin—urinary bladder cancer	0.000219	0.00245	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000218	0.00245	CcSEcCtD
Ezogabine—Fatigue—Thiotepa—urinary bladder cancer	0.000218	0.00244	CcSEcCtD
Ezogabine—Leukopenia—Cisplatin—urinary bladder cancer	0.000217	0.00244	CcSEcCtD
Ezogabine—Constipation—Thiotepa—urinary bladder cancer	0.000216	0.00242	CcSEcCtD
Ezogabine—Discomfort—Fluorouracil—urinary bladder cancer	0.000215	0.00242	CcSEcCtD
Ezogabine—Muscle spasms—Etoposide—urinary bladder cancer	0.000214	0.0024	CcSEcCtD
Ezogabine—Infection—Gemcitabine—urinary bladder cancer	0.000211	0.00237	CcSEcCtD
Ezogabine—Confusional state—Fluorouracil—urinary bladder cancer	0.00021	0.00236	CcSEcCtD
Ezogabine—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.000208	0.00234	CcSEcCtD
Ezogabine—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000208	0.00233	CcSEcCtD
Ezogabine—Thrombocytopenia—Gemcitabine—urinary bladder cancer	0.000208	0.00233	CcSEcCtD
Ezogabine—Infection—Fluorouracil—urinary bladder cancer	0.000207	0.00233	CcSEcCtD
Ezogabine—Diplopia—Epirubicin—urinary bladder cancer	0.000207	0.00232	CcSEcCtD
Ezogabine—Osteoarthritis—Epirubicin—urinary bladder cancer	0.000207	0.00232	CcSEcCtD
Ezogabine—Ill-defined disorder—Etoposide—urinary bladder cancer	0.000206	0.00231	CcSEcCtD
Ezogabine—Anxiety—Cisplatin—urinary bladder cancer	0.000206	0.00231	CcSEcCtD
Ezogabine—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.000205	0.0023	CcSEcCtD
Ezogabine—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.000205	0.0023	CcSEcCtD
Ezogabine—Thrombocytopenia—Fluorouracil—urinary bladder cancer	0.000204	0.00229	CcSEcCtD
Ezogabine—Liver function test abnormal—Methotrexate—urinary bladder cancer	0.000204	0.00229	CcSEcCtD
Ezogabine—Discomfort—Cisplatin—urinary bladder cancer	0.000204	0.00229	CcSEcCtD
Ezogabine—Increased appetite—Doxorubicin—urinary bladder cancer	0.000204	0.00229	CcSEcCtD
Ezogabine—Malaise—Etoposide—urinary bladder cancer	0.0002	0.00225	CcSEcCtD
Ezogabine—Vertigo—Etoposide—urinary bladder cancer	0.0002	0.00224	CcSEcCtD
Ezogabine—Leukopenia—Etoposide—urinary bladder cancer	0.000199	0.00223	CcSEcCtD
Ezogabine—Infection—Cisplatin—urinary bladder cancer	0.000197	0.00221	CcSEcCtD
Ezogabine—Loss of consciousness—Etoposide—urinary bladder cancer	0.000195	0.00219	CcSEcCtD
Ezogabine—Nervous system disorder—Cisplatin—urinary bladder cancer	0.000194	0.00218	CcSEcCtD
Ezogabine—Thrombocytopenia—Cisplatin—urinary bladder cancer	0.000194	0.00218	CcSEcCtD
Ezogabine—Diplopia—Doxorubicin—urinary bladder cancer	0.000191	0.00215	CcSEcCtD
Ezogabine—Osteoarthritis—Doxorubicin—urinary bladder cancer	0.000191	0.00215	CcSEcCtD
Ezogabine—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000191	0.00215	CcSEcCtD
Ezogabine—Liver function test abnormal—Epirubicin—urinary bladder cancer	0.000191	0.00214	CcSEcCtD
Ezogabine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000191	0.00214	CcSEcCtD
Ezogabine—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000189	0.00212	CcSEcCtD
Ezogabine—Somnolence—Gemcitabine—urinary bladder cancer	0.000189	0.00212	CcSEcCtD
Ezogabine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000187	0.0021	CcSEcCtD
Ezogabine—Discomfort—Etoposide—urinary bladder cancer	0.000187	0.0021	CcSEcCtD
Ezogabine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000186	0.00209	CcSEcCtD
Ezogabine—Somnolence—Fluorouracil—urinary bladder cancer	0.000186	0.00208	CcSEcCtD
Ezogabine—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000184	0.00206	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000183	0.00206	CcSEcCtD
Ezogabine—Fatigue—Gemcitabine—urinary bladder cancer	0.000183	0.00205	CcSEcCtD
Ezogabine—Confusional state—Etoposide—urinary bladder cancer	0.000183	0.00205	CcSEcCtD
Ezogabine—Constipation—Gemcitabine—urinary bladder cancer	0.000182	0.00204	CcSEcCtD
Ezogabine—Asthenia—Thiotepa—urinary bladder cancer	0.000181	0.00203	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.00018	0.00202	CcSEcCtD
Ezogabine—Infection—Etoposide—urinary bladder cancer	0.00018	0.00202	CcSEcCtD
Ezogabine—Influenza—Epirubicin—urinary bladder cancer	0.000179	0.00201	CcSEcCtD
Ezogabine—Dysphagia—Epirubicin—urinary bladder cancer	0.000179	0.00201	CcSEcCtD
Ezogabine—Dysuria—Methotrexate—urinary bladder cancer	0.000179	0.002	CcSEcCtD
Ezogabine—Neutropenia—Methotrexate—urinary bladder cancer	0.000179	0.002	CcSEcCtD
Ezogabine—Paraesthesia—Cisplatin—urinary bladder cancer	0.000178	0.00199	CcSEcCtD
Ezogabine—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000177	0.00199	CcSEcCtD
Ezogabine—Liver function test abnormal—Doxorubicin—urinary bladder cancer	0.000177	0.00198	CcSEcCtD
Ezogabine—Dyspnoea—Cisplatin—urinary bladder cancer	0.000176	0.00198	CcSEcCtD
Ezogabine—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000175	0.00197	CcSEcCtD
Ezogabine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000175	0.00196	CcSEcCtD
Ezogabine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000172	0.00193	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000171	0.00192	CcSEcCtD
Ezogabine—Infestation NOS—Methotrexate—urinary bladder cancer	0.00017	0.00191	CcSEcCtD
Ezogabine—Infestation—Methotrexate—urinary bladder cancer	0.00017	0.00191	CcSEcCtD
Ezogabine—Neutropenia—Epirubicin—urinary bladder cancer	0.000167	0.00188	CcSEcCtD
Ezogabine—Dysuria—Epirubicin—urinary bladder cancer	0.000167	0.00188	CcSEcCtD
Ezogabine—Dizziness—Thiotepa—urinary bladder cancer	0.000167	0.00187	CcSEcCtD
Ezogabine—Influenza—Doxorubicin—urinary bladder cancer	0.000165	0.00186	CcSEcCtD
Ezogabine—Dysphagia—Doxorubicin—urinary bladder cancer	0.000165	0.00186	CcSEcCtD
Ezogabine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000163	0.00183	CcSEcCtD
Ezogabine—Paraesthesia—Etoposide—urinary bladder cancer	0.000163	0.00183	CcSEcCtD
Ezogabine—Weight increased—Epirubicin—urinary bladder cancer	0.000163	0.00183	CcSEcCtD
Ezogabine—Haematuria—Methotrexate—urinary bladder cancer	0.000162	0.00182	CcSEcCtD
Ezogabine—Dyspnoea—Etoposide—urinary bladder cancer	0.000162	0.00181	CcSEcCtD
Ezogabine—Somnolence—Etoposide—urinary bladder cancer	0.000161	0.00181	CcSEcCtD
Ezogabine—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000161	0.00181	CcSEcCtD
Ezogabine—Infestation—Epirubicin—urinary bladder cancer	0.000159	0.00179	CcSEcCtD
Ezogabine—Infestation NOS—Epirubicin—urinary bladder cancer	0.000159	0.00179	CcSEcCtD
Ezogabine—Rash—Thiotepa—urinary bladder cancer	0.000159	0.00179	CcSEcCtD
Ezogabine—Dermatitis—Thiotepa—urinary bladder cancer	0.000159	0.00178	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000156	0.00176	CcSEcCtD
Ezogabine—Fatigue—Etoposide—urinary bladder cancer	0.000156	0.00175	CcSEcCtD
Ezogabine—Constipation—Etoposide—urinary bladder cancer	0.000155	0.00174	CcSEcCtD
Ezogabine—Neutropenia—Doxorubicin—urinary bladder cancer	0.000155	0.00174	CcSEcCtD
Ezogabine—Dysuria—Doxorubicin—urinary bladder cancer	0.000155	0.00174	CcSEcCtD
Ezogabine—Asthenia—Gemcitabine—urinary bladder cancer	0.000152	0.00171	CcSEcCtD
Ezogabine—Haematuria—Epirubicin—urinary bladder cancer	0.000152	0.00171	CcSEcCtD
Ezogabine—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.000151	0.00169	CcSEcCtD
Ezogabine—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000151	0.00169	CcSEcCtD
Ezogabine—Weight increased—Doxorubicin—urinary bladder cancer	0.00015	0.00169	CcSEcCtD
Ezogabine—Nausea—Thiotepa—urinary bladder cancer	0.00015	0.00168	CcSEcCtD
Ezogabine—Urethral disorder—Methotrexate—urinary bladder cancer	0.00015	0.00168	CcSEcCtD
Ezogabine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000149	0.00168	CcSEcCtD
Ezogabine—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000147	0.00166	CcSEcCtD
Ezogabine—Infestation—Doxorubicin—urinary bladder cancer	0.000147	0.00166	CcSEcCtD
Ezogabine—Visual impairment—Methotrexate—urinary bladder cancer	0.000147	0.00165	CcSEcCtD
Ezogabine—Eye disorder—Methotrexate—urinary bladder cancer	0.000143	0.0016	CcSEcCtD
Ezogabine—Asthenia—Cisplatin—urinary bladder cancer	0.000142	0.00159	CcSEcCtD
Ezogabine—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000141	0.00159	CcSEcCtD
Ezogabine—Oedema peripheral—Epirubicin—urinary bladder cancer	0.000141	0.00158	CcSEcCtD
Ezogabine—Haematuria—Doxorubicin—urinary bladder cancer	0.000141	0.00158	CcSEcCtD
Ezogabine—Urethral disorder—Epirubicin—urinary bladder cancer	0.00014	0.00157	CcSEcCtD
Ezogabine—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000139	0.00157	CcSEcCtD
Ezogabine—Dizziness—Fluorouracil—urinary bladder cancer	0.000138	0.00155	CcSEcCtD
Ezogabine—Visual impairment—Epirubicin—urinary bladder cancer	0.000138	0.00155	CcSEcCtD
Ezogabine—Alopecia—Methotrexate—urinary bladder cancer	0.000135	0.00152	CcSEcCtD
Ezogabine—Mental disorder—Methotrexate—urinary bladder cancer	0.000134	0.0015	CcSEcCtD
Ezogabine—Rash—Gemcitabine—urinary bladder cancer	0.000134	0.0015	CcSEcCtD
Ezogabine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000134	0.0015	CcSEcCtD
Ezogabine—Eye disorder—Epirubicin—urinary bladder cancer	0.000134	0.0015	CcSEcCtD
Ezogabine—Malnutrition—Methotrexate—urinary bladder cancer	0.000133	0.00149	CcSEcCtD
Ezogabine—Rash—Fluorouracil—urinary bladder cancer	0.000132	0.00148	CcSEcCtD
Ezogabine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000131	0.00148	CcSEcCtD
Ezogabine—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000131	0.00147	CcSEcCtD
Ezogabine—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.00013	0.00146	CcSEcCtD
Ezogabine—Asthenia—Etoposide—urinary bladder cancer	0.00013	0.00146	CcSEcCtD
Ezogabine—Urethral disorder—Doxorubicin—urinary bladder cancer	0.00013	0.00146	CcSEcCtD
Ezogabine—Visual impairment—Doxorubicin—urinary bladder cancer	0.000128	0.00143	CcSEcCtD
Ezogabine—Alopecia—Epirubicin—urinary bladder cancer	0.000126	0.00142	CcSEcCtD
Ezogabine—Nausea—Gemcitabine—urinary bladder cancer	0.000126	0.00142	CcSEcCtD
Ezogabine—Vision blurred—Methotrexate—urinary bladder cancer	0.000125	0.00141	CcSEcCtD
Ezogabine—Mental disorder—Epirubicin—urinary bladder cancer	0.000125	0.00141	CcSEcCtD
Ezogabine—Rash—Cisplatin—urinary bladder cancer	0.000125	0.0014	CcSEcCtD
Ezogabine—Dermatitis—Cisplatin—urinary bladder cancer	0.000125	0.0014	CcSEcCtD
Ezogabine—Malnutrition—Epirubicin—urinary bladder cancer	0.000124	0.0014	CcSEcCtD
Ezogabine—Nausea—Fluorouracil—urinary bladder cancer	0.000124	0.00139	CcSEcCtD
Ezogabine—Eye disorder—Doxorubicin—urinary bladder cancer	0.000124	0.00139	CcSEcCtD
Ezogabine—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000123	0.00139	CcSEcCtD
Ezogabine—Malaise—Methotrexate—urinary bladder cancer	0.00012	0.00135	CcSEcCtD
Ezogabine—Dizziness—Etoposide—urinary bladder cancer	0.00012	0.00135	CcSEcCtD
Ezogabine—Muscle spasms—Epirubicin—urinary bladder cancer	0.00012	0.00134	CcSEcCtD
Ezogabine—Vertigo—Methotrexate—urinary bladder cancer	0.00012	0.00134	CcSEcCtD
Ezogabine—Leukopenia—Methotrexate—urinary bladder cancer	0.000119	0.00134	CcSEcCtD
Ezogabine—Nausea—Cisplatin—urinary bladder cancer	0.000118	0.00132	CcSEcCtD
Ezogabine—Vision blurred—Epirubicin—urinary bladder cancer	0.000117	0.00132	CcSEcCtD
Ezogabine—Alopecia—Doxorubicin—urinary bladder cancer	0.000117	0.00131	CcSEcCtD
Ezogabine—Mental disorder—Doxorubicin—urinary bladder cancer	0.000116	0.0013	CcSEcCtD
Ezogabine—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000116	0.0013	CcSEcCtD
Ezogabine—Malnutrition—Doxorubicin—urinary bladder cancer	0.000115	0.00129	CcSEcCtD
Ezogabine—Rash—Etoposide—urinary bladder cancer	0.000114	0.00128	CcSEcCtD
Ezogabine—Dermatitis—Etoposide—urinary bladder cancer	0.000114	0.00128	CcSEcCtD
Ezogabine—Malaise—Epirubicin—urinary bladder cancer	0.000112	0.00126	CcSEcCtD
Ezogabine—Discomfort—Methotrexate—urinary bladder cancer	0.000112	0.00126	CcSEcCtD
Ezogabine—Vertigo—Epirubicin—urinary bladder cancer	0.000112	0.00126	CcSEcCtD
Ezogabine—Syncope—Epirubicin—urinary bladder cancer	0.000112	0.00125	CcSEcCtD
Ezogabine—Leukopenia—Epirubicin—urinary bladder cancer	0.000111	0.00125	CcSEcCtD
Ezogabine—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000111	0.00124	CcSEcCtD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.00011	0.000819	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.00011	0.000819	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—CYP4B1—urinary bladder cancer	0.00011	0.000816	CbGpPWpGaD
Ezogabine—Confusional state—Methotrexate—urinary bladder cancer	0.000109	0.00123	CcSEcCtD
Ezogabine—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000109	0.00123	CcSEcCtD
Ezogabine—UGT1A1—NRF2 pathway—NQO1—urinary bladder cancer	0.000109	0.000812	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—NQO1—urinary bladder cancer	0.000109	0.000812	CbGpPWpGaD
Ezogabine—Vision blurred—Doxorubicin—urinary bladder cancer	0.000109	0.00122	CcSEcCtD
Ezogabine—Infection—Methotrexate—urinary bladder cancer	0.000108	0.00121	CcSEcCtD
Ezogabine—Nausea—Etoposide—urinary bladder cancer	0.000108	0.00121	CcSEcCtD
Ezogabine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000107	0.0012	CcSEcCtD
Ezogabine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000106	0.0012	CcSEcCtD
Ezogabine—UGT1A3—Biological oxidations—GSTM1—urinary bladder cancer	0.000106	0.00079	CbGpPWpGaD
Ezogabine—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000106	0.00119	CcSEcCtD
Ezogabine—Anxiety—Epirubicin—urinary bladder cancer	0.000106	0.00119	CcSEcCtD
Ezogabine—UGT1A9—PPARA activates gene expression—NCOR1—urinary bladder cancer	0.000105	0.00078	CbGpPWpGaD
Ezogabine—UGT1A3—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000105	0.000779	CbGpPWpGaD
Ezogabine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000105	0.00118	CcSEcCtD
Ezogabine—Discomfort—Epirubicin—urinary bladder cancer	0.000105	0.00118	CcSEcCtD
Ezogabine—NAT2—Metabolism—SLC19A1—urinary bladder cancer	0.000104	0.000771	CbGpPWpGaD
Ezogabine—Malaise—Doxorubicin—urinary bladder cancer	0.000104	0.00117	CcSEcCtD
Ezogabine—Dry mouth—Epirubicin—urinary bladder cancer	0.000104	0.00116	CcSEcCtD
Ezogabine—Vertigo—Doxorubicin—urinary bladder cancer	0.000103	0.00116	CcSEcCtD
Ezogabine—Syncope—Doxorubicin—urinary bladder cancer	0.000103	0.00116	CcSEcCtD
Ezogabine—Leukopenia—Doxorubicin—urinary bladder cancer	0.000103	0.00116	CcSEcCtD
Ezogabine—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—NCOR1—urinary bladder cancer	0.000103	0.000764	CbGpPWpGaD
Ezogabine—Confusional state—Epirubicin—urinary bladder cancer	0.000102	0.00115	CcSEcCtD
Ezogabine—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000101	0.00114	CcSEcCtD
Ezogabine—NAT2—Metabolism—PRSS3—urinary bladder cancer	0.000101	0.000751	CbGpPWpGaD
Ezogabine—Infection—Epirubicin—urinary bladder cancer	0.000101	0.00113	CcSEcCtD
Ezogabine—Shock—Epirubicin—urinary bladder cancer	0.0001	0.00112	CcSEcCtD
Ezogabine—Nervous system disorder—Epirubicin—urinary bladder cancer	9.96e-05	0.00112	CcSEcCtD
Ezogabine—Thrombocytopenia—Epirubicin—urinary bladder cancer	9.95e-05	0.00112	CcSEcCtD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	9.91e-05	0.000735	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	9.91e-05	0.000735	CbGpPWpGaD
Ezogabine—Hyperhidrosis—Epirubicin—urinary bladder cancer	9.82e-05	0.0011	CcSEcCtD
Ezogabine—Anxiety—Doxorubicin—urinary bladder cancer	9.77e-05	0.0011	CcSEcCtD
Ezogabine—Paraesthesia—Methotrexate—urinary bladder cancer	9.75e-05	0.00109	CcSEcCtD
Ezogabine—Discomfort—Doxorubicin—urinary bladder cancer	9.69e-05	0.00109	CcSEcCtD
Ezogabine—Dyspnoea—Methotrexate—urinary bladder cancer	9.68e-05	0.00109	CcSEcCtD
Ezogabine—Somnolence—Methotrexate—urinary bladder cancer	9.65e-05	0.00108	CcSEcCtD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	9.63e-05	0.000715	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	9.63e-05	0.000715	CbGpPWpGaD
Ezogabine—Dry mouth—Doxorubicin—urinary bladder cancer	9.59e-05	0.00108	CcSEcCtD
Ezogabine—Dyspepsia—Methotrexate—urinary bladder cancer	9.56e-05	0.00107	CcSEcCtD
Ezogabine—Confusional state—Doxorubicin—urinary bladder cancer	9.48e-05	0.00106	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	9.37e-05	0.00105	CcSEcCtD
Ezogabine—Fatigue—Methotrexate—urinary bladder cancer	9.36e-05	0.00105	CcSEcCtD
Ezogabine—Infection—Doxorubicin—urinary bladder cancer	9.34e-05	0.00105	CcSEcCtD
Ezogabine—Shock—Doxorubicin—urinary bladder cancer	9.25e-05	0.00104	CcSEcCtD
Ezogabine—Nervous system disorder—Doxorubicin—urinary bladder cancer	9.22e-05	0.00104	CcSEcCtD
Ezogabine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	9.2e-05	0.00103	CcSEcCtD
Ezogabine—CYP2A6—Biological oxidations—HPGDS—urinary bladder cancer	9.18e-05	0.000681	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—GSTP1—urinary bladder cancer	9.13e-05	0.000677	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—GSTP1—urinary bladder cancer	9.13e-05	0.000677	CbGpPWpGaD
Ezogabine—Paraesthesia—Epirubicin—urinary bladder cancer	9.12e-05	0.00102	CcSEcCtD
Ezogabine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	9.09e-05	0.00102	CcSEcCtD
Ezogabine—Dyspnoea—Epirubicin—urinary bladder cancer	9.06e-05	0.00102	CcSEcCtD
Ezogabine—Somnolence—Epirubicin—urinary bladder cancer	9.03e-05	0.00101	CcSEcCtD
Ezogabine—Feeling abnormal—Methotrexate—urinary bladder cancer	8.95e-05	0.001	CcSEcCtD
Ezogabine—Dyspepsia—Epirubicin—urinary bladder cancer	8.94e-05	0.001	CcSEcCtD
Ezogabine—CYP2A6—Biological oxidations—GSTT1—urinary bladder cancer	8.9e-05	0.00066	CbGpPWpGaD
Ezogabine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	8.77e-05	0.000985	CcSEcCtD
Ezogabine—Fatigue—Epirubicin—urinary bladder cancer	8.76e-05	0.000984	CcSEcCtD
Ezogabine—Constipation—Epirubicin—urinary bladder cancer	8.69e-05	0.000976	CcSEcCtD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	8.59e-05	0.000638	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—NCOR1—urinary bladder cancer	8.54e-05	0.000634	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—NCOR1—urinary bladder cancer	8.54e-05	0.000634	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—GSTZ1—urinary bladder cancer	8.54e-05	0.000633	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	8.44e-05	0.000626	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	8.44e-05	0.000626	CbGpPWpGaD
Ezogabine—Paraesthesia—Doxorubicin—urinary bladder cancer	8.44e-05	0.000948	CcSEcCtD
Ezogabine—CYP2A6—NRF2 pathway—NQO1—urinary bladder cancer	8.43e-05	0.000626	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—GSTM1—urinary bladder cancer	8.39e-05	0.000622	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—GSTM1—urinary bladder cancer	8.39e-05	0.000622	CbGpPWpGaD
Ezogabine—Dyspnoea—Doxorubicin—urinary bladder cancer	8.38e-05	0.000941	CcSEcCtD
Ezogabine—Feeling abnormal—Epirubicin—urinary bladder cancer	8.37e-05	0.00094	CcSEcCtD
Ezogabine—Somnolence—Doxorubicin—urinary bladder cancer	8.36e-05	0.000938	CcSEcCtD
Ezogabine—Dyspepsia—Doxorubicin—urinary bladder cancer	8.28e-05	0.000929	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	8.12e-05	0.000911	CcSEcCtD
Ezogabine—Fatigue—Doxorubicin—urinary bladder cancer	8.1e-05	0.00091	CcSEcCtD
Ezogabine—UGT1A4—Metabolism—GSTO2—urinary bladder cancer	8.09e-05	0.0006	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—NAT1—urinary bladder cancer	8.09e-05	0.0006	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—TYMP—urinary bladder cancer	8.09e-05	0.0006	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	8.04e-05	0.000596	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	8.04e-05	0.000596	CbGpPWpGaD
Ezogabine—Constipation—Doxorubicin—urinary bladder cancer	8.04e-05	0.000903	CcSEcCtD
Ezogabine—KCNQ5—Neuronal System—HRAS—urinary bladder cancer	8.02e-05	0.000595	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—HRAS—urinary bladder cancer	8.02e-05	0.000595	CbGpPWpGaD
Ezogabine—UGT1A1—Biological oxidations—GSTP1—urinary bladder cancer	8e-05	0.000594	CbGpPWpGaD
Ezogabine—UGT1A9—Biological oxidations—GSTP1—urinary bladder cancer	8e-05	0.000594	CbGpPWpGaD
Ezogabine—UGT1A1—Metapathway biotransformation—GSTP1—urinary bladder cancer	7.89e-05	0.000586	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—GSTP1—urinary bladder cancer	7.89e-05	0.000586	CbGpPWpGaD
Ezogabine—Asthenia—Methotrexate—urinary bladder cancer	7.79e-05	0.000875	CcSEcCtD
Ezogabine—Feeling abnormal—Doxorubicin—urinary bladder cancer	7.75e-05	0.00087	CcSEcCtD
Ezogabine—UGT1A9—PPARA activates gene expression—PPARG—urinary bladder cancer	7.54e-05	0.000559	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—RHOA—urinary bladder cancer	7.46e-05	0.000553	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—RHOA—urinary bladder cancer	7.46e-05	0.000553	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—UGT2B7—urinary bladder cancer	7.4e-05	0.000549	CbGpPWpGaD
Ezogabine—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—PPARG—urinary bladder cancer	7.38e-05	0.000547	CbGpPWpGaD
Ezogabine—UGT1A1—Biological oxidations—GSTM1—urinary bladder cancer	7.36e-05	0.000546	CbGpPWpGaD
Ezogabine—UGT1A9—Biological oxidations—GSTM1—urinary bladder cancer	7.36e-05	0.000546	CbGpPWpGaD
Ezogabine—Asthenia—Epirubicin—urinary bladder cancer	7.29e-05	0.000819	CcSEcCtD
Ezogabine—UGT1A1—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.25e-05	0.000538	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—GSTM1—urinary bladder cancer	7.25e-05	0.000538	CbGpPWpGaD
Ezogabine—UGT1A9—PPARA activates gene expression—CREBBP—urinary bladder cancer	7.24e-05	0.000537	CbGpPWpGaD
Ezogabine—Dizziness—Methotrexate—urinary bladder cancer	7.18e-05	0.000806	CcSEcCtD
Ezogabine—CYP2A6—Fluoropyrimidine Activity—TP53—urinary bladder cancer	7.13e-05	0.000529	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GSTZ1—urinary bladder cancer	7.1e-05	0.000526	CbGpPWpGaD
Ezogabine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—NCOR1—urinary bladder cancer	7.09e-05	0.000526	CbGpPWpGaD
Ezogabine—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—CREBBP—urinary bladder cancer	7.09e-05	0.000526	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—GSTP1—urinary bladder cancer	7.03e-05	0.000522	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—ERBB2—urinary bladder cancer	6.9e-05	0.000512	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—ERBB2—urinary bladder cancer	6.9e-05	0.000512	CbGpPWpGaD
Ezogabine—Rash—Methotrexate—urinary bladder cancer	6.85e-05	0.000769	CcSEcCtD
Ezogabine—Dermatitis—Methotrexate—urinary bladder cancer	6.84e-05	0.000768	CcSEcCtD
Ezogabine—Asthenia—Doxorubicin—urinary bladder cancer	6.74e-05	0.000757	CcSEcCtD
Ezogabine—KCNQ3—Developmental Biology—CDK4—urinary bladder cancer	6.74e-05	0.0005	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—CDK4—urinary bladder cancer	6.74e-05	0.0005	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GSTO2—urinary bladder cancer	6.73e-05	0.000499	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—NAT1—urinary bladder cancer	6.73e-05	0.000499	CbGpPWpGaD
Ezogabine—Dizziness—Epirubicin—urinary bladder cancer	6.72e-05	0.000754	CcSEcCtD
Ezogabine—UGT1A4—Metabolism—CYP4B1—urinary bladder cancer	6.66e-05	0.000494	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—GSTM1—urinary bladder cancer	6.46e-05	0.00048	CbGpPWpGaD
Ezogabine—Nausea—Methotrexate—urinary bladder cancer	6.45e-05	0.000724	CcSEcCtD
Ezogabine—Rash—Epirubicin—urinary bladder cancer	6.41e-05	0.000719	CcSEcCtD
Ezogabine—Dermatitis—Epirubicin—urinary bladder cancer	6.4e-05	0.000719	CcSEcCtD
Ezogabine—NAT2—Metabolism—RRM2—urinary bladder cancer	6.32e-05	0.000469	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—SLC19A1—urinary bladder cancer	6.29e-05	0.000467	CbGpPWpGaD
Ezogabine—Dizziness—Doxorubicin—urinary bladder cancer	6.22e-05	0.000698	CcSEcCtD
Ezogabine—CYP2A6—Biological oxidations—GSTP1—urinary bladder cancer	6.17e-05	0.000458	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—UGT2B7—urinary bladder cancer	6.15e-05	0.000456	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PRSS3—urinary bladder cancer	6.13e-05	0.000455	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—PPARG—urinary bladder cancer	6.12e-05	0.000454	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—PPARG—urinary bladder cancer	6.12e-05	0.000454	CbGpPWpGaD
Ezogabine—Nausea—Epirubicin—urinary bladder cancer	6.03e-05	0.000678	CcSEcCtD
Ezogabine—Rash—Doxorubicin—urinary bladder cancer	5.93e-05	0.000666	CcSEcCtD
Ezogabine—Dermatitis—Doxorubicin—urinary bladder cancer	5.92e-05	0.000665	CcSEcCtD
Ezogabine—KCNQ3—Axon guidance—MMP9—urinary bladder cancer	5.92e-05	0.000439	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—MMP9—urinary bladder cancer	5.92e-05	0.000439	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—CREBBP—urinary bladder cancer	5.88e-05	0.000436	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—CREBBP—urinary bladder cancer	5.88e-05	0.000436	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—HPGDS—urinary bladder cancer	5.85e-05	0.000434	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—ENO2—urinary bladder cancer	5.85e-05	0.000434	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—GSTT1—urinary bladder cancer	5.67e-05	0.000421	CbGpPWpGaD
Ezogabine—CYP2A6—Biological oxidations—GSTM1—urinary bladder cancer	5.67e-05	0.000421	CbGpPWpGaD
Ezogabine—Nausea—Doxorubicin—urinary bladder cancer	5.58e-05	0.000627	CcSEcCtD
Ezogabine—UGT1A3—Metabolism—CYP4B1—urinary bladder cancer	5.54e-05	0.000411	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—SRC—urinary bladder cancer	5.46e-05	0.000405	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—SRC—urinary bladder cancer	5.46e-05	0.000405	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—RHOA—urinary bladder cancer	5.32e-05	0.000395	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—RHOA—urinary bladder cancer	5.32e-05	0.000395	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—SLC19A1—urinary bladder cancer	5.23e-05	0.000388	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PRSS3—urinary bladder cancer	5.1e-05	0.000378	CbGpPWpGaD
Ezogabine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—PPARG—urinary bladder cancer	5.08e-05	0.000377	CbGpPWpGaD
Ezogabine—UGT1A9—PPARA activates gene expression—EP300—urinary bladder cancer	4.93e-05	0.000366	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—ERBB2—urinary bladder cancer	4.93e-05	0.000365	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—ERBB2—urinary bladder cancer	4.93e-05	0.000365	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—TYMP—urinary bladder cancer	4.9e-05	0.000364	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GSTZ1—urinary bladder cancer	4.9e-05	0.000364	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GSTZ1—urinary bladder cancer	4.9e-05	0.000364	CbGpPWpGaD
Ezogabine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—CREBBP—urinary bladder cancer	4.88e-05	0.000362	CbGpPWpGaD
Ezogabine—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—EP300—urinary bladder cancer	4.83e-05	0.000358	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—EGFR—urinary bladder cancer	4.79e-05	0.000355	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—EGFR—urinary bladder cancer	4.79e-05	0.000355	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—NQO1—urinary bladder cancer	4.72e-05	0.00035	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GSTO2—urinary bladder cancer	4.65e-05	0.000345	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—NAT1—urinary bladder cancer	4.65e-05	0.000345	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GSTO2—urinary bladder cancer	4.65e-05	0.000345	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—NAT1—urinary bladder cancer	4.65e-05	0.000345	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	4.57e-05	0.000339	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—KRAS—urinary bladder cancer	4.52e-05	0.000335	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—KRAS—urinary bladder cancer	4.52e-05	0.000335	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—NAT2—urinary bladder cancer	4.43e-05	0.000329	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—HRAS—urinary bladder cancer	4.33e-05	0.000321	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—HRAS—urinary bladder cancer	4.33e-05	0.000321	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—UGT2B7—urinary bladder cancer	4.25e-05	0.000315	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—UGT2B7—urinary bladder cancer	4.25e-05	0.000315	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—MMP9—urinary bladder cancer	4.23e-05	0.000313	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—MMP9—urinary bladder cancer	4.23e-05	0.000313	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—TYMP—urinary bladder cancer	4.08e-05	0.000302	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—EP300—urinary bladder cancer	4.01e-05	0.000297	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—EP300—urinary bladder cancer	4.01e-05	0.000297	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—GSTP1—urinary bladder cancer	3.93e-05	0.000292	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—SRC—urinary bladder cancer	3.9e-05	0.000289	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—SRC—urinary bladder cancer	3.9e-05	0.000289	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—HRAS—urinary bladder cancer	3.84e-05	0.000285	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—HRAS—urinary bladder cancer	3.84e-05	0.000285	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—RRM2—urinary bladder cancer	3.83e-05	0.000284	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CYP4B1—urinary bladder cancer	3.83e-05	0.000284	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CYP4B1—urinary bladder cancer	3.83e-05	0.000284	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GSTZ1—urinary bladder cancer	3.78e-05	0.00028	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—NAT2—urinary bladder cancer	3.69e-05	0.000273	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—TYMS—urinary bladder cancer	3.66e-05	0.000271	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—SLC19A1—urinary bladder cancer	3.61e-05	0.000268	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—SLC19A1—urinary bladder cancer	3.61e-05	0.000268	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—GSTM1—urinary bladder cancer	3.61e-05	0.000268	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—NCOR1—urinary bladder cancer	3.61e-05	0.000268	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—NAT1—urinary bladder cancer	3.58e-05	0.000266	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GSTO2—urinary bladder cancer	3.58e-05	0.000266	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—HPGDS—urinary bladder cancer	3.54e-05	0.000263	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—ENO2—urinary bladder cancer	3.54e-05	0.000263	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PRSS3—urinary bladder cancer	3.52e-05	0.000261	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PRSS3—urinary bladder cancer	3.52e-05	0.000261	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—GPX1—urinary bladder cancer	3.46e-05	0.000257	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—GSTT1—urinary bladder cancer	3.44e-05	0.000255	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—EGFR—urinary bladder cancer	3.41e-05	0.000253	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—EGFR—urinary bladder cancer	3.41e-05	0.000253	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—ERCC2—urinary bladder cancer	3.4e-05	0.000252	CbGpPWpGaD
Ezogabine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	3.33e-05	0.000247	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—UGT2B7—urinary bladder cancer	3.28e-05	0.000243	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—TNF—urinary bladder cancer	3.25e-05	0.000241	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—TNF—urinary bladder cancer	3.25e-05	0.000241	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—KRAS—urinary bladder cancer	3.23e-05	0.000239	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—KRAS—urinary bladder cancer	3.23e-05	0.000239	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—MTHFR—urinary bladder cancer	3.19e-05	0.000237	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—RRM2—urinary bladder cancer	3.18e-05	0.000236	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CYP4B1—urinary bladder cancer	2.95e-05	0.000219	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—HPGDS—urinary bladder cancer	2.95e-05	0.000219	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—ENO2—urinary bladder cancer	2.95e-05	0.000219	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GSTT1—urinary bladder cancer	2.86e-05	0.000212	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—NQO1—urinary bladder cancer	2.86e-05	0.000212	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	2.82e-05	0.00021	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—TYMP—urinary bladder cancer	2.82e-05	0.000209	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—TYMP—urinary bladder cancer	2.82e-05	0.000209	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—SLC19A1—urinary bladder cancer	2.79e-05	0.000207	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—HRAS—urinary bladder cancer	2.74e-05	0.000203	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—HRAS—urinary bladder cancer	2.74e-05	0.000203	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PRSS3—urinary bladder cancer	2.72e-05	0.000201	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	2.7e-05	0.000201	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PPARG—urinary bladder cancer	2.59e-05	0.000192	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—NAT2—urinary bladder cancer	2.55e-05	0.000189	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—NAT2—urinary bladder cancer	2.55e-05	0.000189	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—CREBBP—urinary bladder cancer	2.49e-05	0.000185	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—GSTP1—urinary bladder cancer	2.38e-05	0.000177	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—NQO1—urinary bladder cancer	2.38e-05	0.000176	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—TYMS—urinary bladder cancer	2.22e-05	0.000164	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—RRM2—urinary bladder cancer	2.2e-05	0.000163	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—RRM2—urinary bladder cancer	2.2e-05	0.000163	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—NCOR1—urinary bladder cancer	2.19e-05	0.000162	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—GSTM1—urinary bladder cancer	2.19e-05	0.000162	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—TYMP—urinary bladder cancer	2.17e-05	0.000161	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—GPX1—urinary bladder cancer	2.1e-05	0.000156	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—ERCC2—urinary bladder cancer	2.06e-05	0.000153	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PTGS2—urinary bladder cancer	2.04e-05	0.000151	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ENO2—urinary bladder cancer	2.04e-05	0.000151	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ENO2—urinary bladder cancer	2.04e-05	0.000151	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—HPGDS—urinary bladder cancer	2.04e-05	0.000151	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—HPGDS—urinary bladder cancer	2.04e-05	0.000151	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.02e-05	0.00015	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GSTP1—urinary bladder cancer	1.98e-05	0.000147	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GSTT1—urinary bladder cancer	1.97e-05	0.000146	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GSTT1—urinary bladder cancer	1.97e-05	0.000146	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—NAT2—urinary bladder cancer	1.96e-05	0.000146	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	1.94e-05	0.000144	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—MTHFR—urinary bladder cancer	1.94e-05	0.000144	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—TYMS—urinary bladder cancer	1.84e-05	0.000137	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—NCOR1—urinary bladder cancer	1.82e-05	0.000135	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GSTM1—urinary bladder cancer	1.82e-05	0.000135	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PTEN—urinary bladder cancer	1.78e-05	0.000132	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—GPX1—urinary bladder cancer	1.74e-05	0.000129	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—ERCC2—urinary bladder cancer	1.71e-05	0.000127	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—EP300—urinary bladder cancer	1.69e-05	0.000126	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—RRM2—urinary bladder cancer	1.69e-05	0.000126	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—NQO1—urinary bladder cancer	1.64e-05	0.000122	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—NQO1—urinary bladder cancer	1.64e-05	0.000122	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—MTHFR—urinary bladder cancer	1.61e-05	0.000119	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.59e-05	0.000118	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PPARG—urinary bladder cancer	1.57e-05	0.000116	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—HPGDS—urinary bladder cancer	1.57e-05	0.000116	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ENO2—urinary bladder cancer	1.57e-05	0.000116	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GSTT1—urinary bladder cancer	1.52e-05	0.000113	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CREBBP—urinary bladder cancer	1.51e-05	0.000112	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.39e-05	0.000103	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GSTP1—urinary bladder cancer	1.37e-05	0.000102	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GSTP1—urinary bladder cancer	1.37e-05	0.000102	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.32e-05	9.82e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PPARG—urinary bladder cancer	1.3e-05	9.68e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—TYMS—urinary bladder cancer	1.27e-05	9.44e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—TYMS—urinary bladder cancer	1.27e-05	9.44e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—NQO1—urinary bladder cancer	1.27e-05	9.38e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GSTM1—urinary bladder cancer	1.26e-05	9.33e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GSTM1—urinary bladder cancer	1.26e-05	9.33e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—NCOR1—urinary bladder cancer	1.26e-05	9.33e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—NCOR1—urinary bladder cancer	1.26e-05	9.33e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CREBBP—urinary bladder cancer	1.25e-05	9.3e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PTGS2—urinary bladder cancer	1.23e-05	9.16e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—GPX1—urinary bladder cancer	1.2e-05	8.94e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—GPX1—urinary bladder cancer	1.2e-05	8.94e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ERCC2—urinary bladder cancer	1.18e-05	8.77e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ERCC2—urinary bladder cancer	1.18e-05	8.77e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—MTHFR—urinary bladder cancer	1.11e-05	8.25e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—MTHFR—urinary bladder cancer	1.11e-05	8.25e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PTEN—urinary bladder cancer	1.08e-05	7.99e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GSTP1—urinary bladder cancer	1.06e-05	7.83e-05	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—EP300—urinary bladder cancer	1.03e-05	7.62e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PTGS2—urinary bladder cancer	1.03e-05	7.61e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—TYMS—urinary bladder cancer	9.81e-06	7.28e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GSTM1—urinary bladder cancer	9.7e-06	7.19e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—NCOR1—urinary bladder cancer	9.7e-06	7.19e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—GPX1—urinary bladder cancer	9.29e-06	6.89e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ERCC2—urinary bladder cancer	9.12e-06	6.76e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PPARG—urinary bladder cancer	9.01e-06	6.69e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PPARG—urinary bladder cancer	9.01e-06	6.69e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PTEN—urinary bladder cancer	8.95e-06	6.64e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CREBBP—urinary bladder cancer	8.66e-06	6.42e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CREBBP—urinary bladder cancer	8.66e-06	6.42e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—MTHFR—urinary bladder cancer	8.57e-06	6.36e-05	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—EP300—urinary bladder cancer	8.54e-06	6.33e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PTGS2—urinary bladder cancer	7.09e-06	5.26e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PTGS2—urinary bladder cancer	7.09e-06	5.26e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PPARG—urinary bladder cancer	6.95e-06	5.15e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CREBBP—urinary bladder cancer	6.68e-06	4.95e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PTEN—urinary bladder cancer	6.18e-06	4.59e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PTEN—urinary bladder cancer	6.18e-06	4.59e-05	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—EP300—urinary bladder cancer	5.9e-06	4.37e-05	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—EP300—urinary bladder cancer	5.9e-06	4.37e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PTGS2—urinary bladder cancer	5.47e-06	4.05e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PTEN—urinary bladder cancer	4.77e-06	3.54e-05	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—EP300—urinary bladder cancer	4.55e-06	3.37e-05	CbGpPWpGaD
